Compare Travere Therapeutics Inc. Common Stock (TVTX) vs United Airlines Holdings Inc (UAL) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

United Airlines (UAL) stock trades at $98.96, down 5.25% on the day, reflecting near-term pressure. The company maintains strong fundamentals with a P/E of 9.67 and robust profitability, including a 5.56% net margin and 23.25% ROE. Recent earnings have consistently beaten estimates, and analysts project a consensus price target of $158.10. However, technical indicators signal a bearish trend, and cash flow turned negative in 2025 due to elevated capital expenditures.

The outlook for UAL is mixed. Strong earnings momentum, market share gains from aggressive customer acquisition, and attractive valuation multiples support upside potential. Key risks include volatile fuel costs, competitive intensity, and debt levels. With no sell ratings from analysts and institutional confidence, the stock presents a compelling opportunity for value-oriented investors despite near-term technical weakness.